Ken Cacciatore
Stock Analyst at TD Cowen
(0.41)
# 3,287
Out of 4,479 analysts
13
Total ratings
25%
Success rate
-30.11%
Average return
Main Sectors:
10 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $65 → $50 | $9.30 | +437.63% | 2 | Aug 9, 2023 | |
| BHC Bausch Health Companies | Downgrades: Market Perform | n/a | $7.11 | - | 1 | Jun 16, 2023 | |
| TAK Takeda Pharmaceutical | Maintains: Outperform | $30 → $20 | $13.03 | +53.49% | 3 | May 16, 2023 | |
| SCPH scPharmaceuticals | Initiates: Outperform | $25 | $4.21 | +493.82% | 1 | Dec 1, 2022 | |
| BLCO Bausch + Lomb | Initiates: Outperform | $35 | $14.66 | +138.74% | 1 | May 11, 2022 | |
| MOLN Molecular Partners AG | Initiates: Outperform | n/a | $7.00 | - | 1 | Jul 13, 2021 | |
| TARA Protara Therapeutics | Initiates: Outperform | n/a | $2.03 | - | 1 | Oct 19, 2020 | |
| BHVN Biohaven Pharmaceutical Holding Company | Initiates: Outperform | n/a | $34.17 | - | 1 | Apr 17, 2020 | |
| AMRN Amarin Corporation | Initiates: Outperform | n/a | $0.71 | - | 1 | Mar 2, 2020 | |
| OPTN OptiNose | Initiates: Outperform | n/a | $1.04 | - | 1 | Dec 18, 2019 |
Arcutis Biotherapeutics
Aug 9, 2023
Maintains: Outperform
Price Target: $65 → $50
Current: $9.30
Upside: +437.63%
Bausch Health Companies
Jun 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $7.11
Upside: -
Takeda Pharmaceutical
May 16, 2023
Maintains: Outperform
Price Target: $30 → $20
Current: $13.03
Upside: +53.49%
scPharmaceuticals
Dec 1, 2022
Initiates: Outperform
Price Target: $25
Current: $4.21
Upside: +493.82%
Bausch + Lomb
May 11, 2022
Initiates: Outperform
Price Target: $35
Current: $14.66
Upside: +138.74%
Molecular Partners AG
Jul 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $7.00
Upside: -
Protara Therapeutics
Oct 19, 2020
Initiates: Outperform
Price Target: n/a
Current: $2.03
Upside: -
Biohaven Pharmaceutical Holding Company
Apr 17, 2020
Initiates: Outperform
Price Target: n/a
Current: $34.17
Upside: -
Amarin Corporation
Mar 2, 2020
Initiates: Outperform
Price Target: n/a
Current: $0.71
Upside: -
OptiNose
Dec 18, 2019
Initiates: Outperform
Price Target: n/a
Current: $1.04
Upside: -